Accedi
Accedi
Oppure accedi con
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registrazione
Oppure accedi con
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Home
  2. Azioni
  3. Svezia
  4. Nasdaq Stockholm
  5. Hansa Biopharma AB (publ)
  6. Notizie
  7. Altre lingue
    HNSA   SE0002148817

HANSA BIOPHARMA AB (PUBL)

(HNSA)
  Rapporto
Tempo reale stimato Cboe Europe  -  09:12 28/11/2022
56.63 SEK   +2.58%
02/11Hansa Biopharma AB e il partner Sarepta Therapeutics intendono avviare uno studio clinico con l'imlifidasi come pre-trattamento della terapia genica SRP-9001 di Sarepta nella DMD nel 2023.
CI
20/10Hansa Biopharma AB (publ) riporta i risultati degli utili per il terzo trimestre e i nove mesi terminati il 30 settembre 2022
CI
12/09Hansa Biopharma ottiene la raccomandazione del Consorzio scozzese per il farmaco per il trapianto renale
MT
RiassuntoQuotazioniGraficiNotizieRatingCalendarioSocietąFinanzaConsensusRevisioniDerivatiFondi 
RiassuntoTutte le notizieAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su HANSA BIOPHARMA AB (PUBL)
02/11Hansa Biopharma and partner Sarepta Therapeutics plan to initiate a clinical study with..
02/11Hansa Biopharma AB and Partner Sarepta Therapeutics Plan to Initiate A Clinical Study w..
31/10Hansa Biopharma: Increase of the number of shares and votes
20/10Transcript : Hansa Biopharma AB, Nine Months 2022 Earnings Call, Oct 20, 2022
20/10Hansa Biopharma Interim report January-September 2022
20/10Hansa Biopharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended..
30/09Hansa Biopharma: Increase of the number of shares and votes
30/09Hansa Biopharma to host conference call to provide interim results for January-Septembe..
30/09Hansa Biopharma achieves Great Place to Work certification for the third consecutive ye..
13/09The Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma's Idefirix (i..
12/09Hansa Biopharma Secures Scottish Consortium's Recommendation for Kidney Transplant Drug
12/09The Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma's Idefirix (i..
12/09The Scottish Medicines Consortium Recommends Use of Hansa Biopharma's Idefirix[®] as De..
09/09Hansa Biopharma: Issue and repurchase of class C shares for incentive programs
22/08Polish Health Ministry Adds Hansa Biopharma's, Medison's Kidney Transplant Drug to Reim..
22/08Hansa Biopharma and Medison Pharma announce positive reimbursement decision in Poland f..
10/08European Society for Organ Transplantation's (ESOT) guidelines for desensitization trea..
19/07Transcript : Hansa Biopharma AB, H1 2022 Earnings Call, Jul 19, 2022
19/07Hansa Biopharma half year report 2022
19/07Hansa Biopharma AB Reports Earnings Results for the Second Quarter and Six Months Ended..
19/07Hansa Biopharma Secures $70 Million Financing From NovaQuest Capital
18/07Hansa Biopharma announces $70 million non-dilutive product finance transaction with Nov..
18/07Hansa Biopharma AB announced that it has received $70 million in funding from NovaQuest..
11/07Hansa Biopharma Treats First Patient In Late-stage Post-authorization Efficacy Study Fo..
11/07Hansa Biopharma announces first patient treated in the post-authorization efficacy stud..
11/07Hansa Biopharma Announces First Patient Treated in the Post-Authorization Efficacy Stud..
30/06Increase of the number of votes in Hansa Biopharma
30/06Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)
30/06Hansa Biopharma AB Appoints Peter Nicklin as A New Member of the Board of Director
30/06Hansa Biopharma to host conference call to provide half year results for January-June 2..
16/06Hansa Biopharma Gets UK Regulator's Recommendation For Kidney Transplant Desensitizatio..
16/06NICE recommends use of Hansa Biopharma's Idefirix® (imlifidase) as desensitization trea..
16/06NICE Recommends Use of Hansa Biopharma's Idefirix as Desensitization Treatment for High..
30/05Hansa Biopharma AB's Current Chair Ulf Wiinberg Has Chosen to Not Stand for Re-Election
30/05Hansa Biopharma: Notice to Annual General Meeting
30/05Hansa Biopharma AB Announces Ulf Wiinberg Not to Stand for Re-Election as Director
30/05The Nomination Committee in Hansa Biopharma proposes Peter Nicklin as new chair of the ..
30/05Hansa Biopharma AB Announces Not Stand for Re-Election of Ulf Wiinberg as Chairman of t..
23/05Hansa Biopharma Finalizes Patient Recruitment in Mid-Stage Study of Kidney Transplant D..
23/05Hansa Biopharma completes enrollment in imlifidase phase 2 study in antibody mediated r..
23/05Hansa Biopharma Completes Enrollment in Imlifidase Phase 2 Study in Antibody Mediated R..
13/05Hansa Biopharma Wins Temporary Marketing Nod For Kidney Transplantation Drug In Switzer..
13/05Hansa Biopharma announces temporary marketing authorization in Switzerland for Idefirix..
13/05Hansa Biopharma Announces Temporary Marketing Authorization in Switzerland for Idefirix..
21/04Transcript : Hansa Biopharma AB, Q1 2022 Earnings Call, Apr 21, 2022
21/04Hansa Biopharma interim report January - March 2022
21/04Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2022
21/04Hansa Biopharma's Idefirix Wins ASMR 3 Status From French Transparency Commission
20/04Hansa Biopharma granted added benefit ASMR 3 by French Transparency Commission for Idef..
19/04US FDA Approves Hansa Biopharma's Investigational New Drug Application For Autoimmune D..
19/04Hansa Biopharma announces U.S. FDA acceptance of Investigational New Drug (IND) applica..
19/04Hansa Biopharma Announces U.S. Fda Acceptance of Investigational New Drug Application f..
08/04Hansa Biopharma: to host conference call to provide interim results for January-March 202..
07/04Hansa Biopharma publishes Annual Report 2021
28/03Hansa Biopharma Up 6% After Israel Approves Idefirix
28/03Hansa Biopharma and Medison Pharma announce marketing authorization in Israel for Idefi..
28/03Hansa Biopharma AB and Medison Pharma Announces Marketing Authorization in Israel for I..
15/03Hansa Biopharma Signs Agreement For Kidney Transplant Treatment Reimbursement In German..
15/03Hansa Biopharma and German payer head association agree on reimbursement price for Idef..
10/03Transcript : Hansa Biopharma AB - Special Call
09/03Hansa Biopharma's Anti-GBM Disease Drug Shows Potential In Phase Two Trial
08/03Key data demonstrating the potential of Hansa Biopharma's imlifidase to significantly a..
08/03Hansa Biopharma AB Demonstrates the Potential of Hansa Biopharma's Imlifidase to Signif..
28/02Hansa Biopharma Gets Positive Early Access Decision in France For Idefirix in Kidney Tr..
25/02Hansa Biopharma announces positive early access decision by French Haute Autorité de Sa..
25/02Hansa Biopharma AB Announces Grant of Early Access Post Marketing Authorization for its..
25/02Hansa Biopharma AB Announces Positive Early Access Decision by French Haute Autorité De..
03/02Transcript : Hansa Biopharma AB, 2021 Earnings Call, Feb 03, 2022
03/02Hansa Biopharma year-end report 2021
03/02Hansa Biopharma AB Reports Earnings Results for the Full Year Ended December 31, 2021
03/02Hansa Biopharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2..
20/01Hansa Biopharma to host conference call to provide Year-End report for 2021 and Busines..
09/01Hansa Biopharma provides business update including certain key financials
04/01Hansa Biopharma, Bayer Unit To Jointly Develop Rare Genetic Disorder Drug
03/01Hansa Biopharma enters into agreement with AskBio to evaluate feasibility of imlifidase..
03/01Hansa Biopharma Enters into Agreement with Askbio to Evaluate Feasibility of Imlifidase..
2021Increase of the number of shares and votes in Hansa Biopharma AB
2021Hansa Biopharma Enrolls First Patient In Kidney Transplant Drug Trial
2021Hansa Biopharma enrolls first patient in U.S. randomized, controlled pivotal trial of i..
2021Hansa Biopharma Enrolls First Patient in U.S. Randomized, Controlled Pivotal Trial of i..
2021Hansa Biopharma: Issue and repurchase of class C shares for incentive programs
2021Hansa Biopharma, Medison Pharma Enter Commercialization Partnership for Kidney Transpla..
2021Hansa Biopharma and Medison Pharma announce multiregional commercialization partnership..
2021Hansa Biopharma AB and Medison Pharma Announce Multiregional Commercialization Partners..
2021Hansa Biopharma Starts Phase 3 For Autoimmune Drug Imlifidase; Shares Up 7%
2021Hansa Biopharma to initiate Phase 3 study of imlifidase to treat anti-Glomerular Baseme..
2021Hansa Biopharma AB Announces its Decision to Initiate a Pivotal Phase 3 Clinical Study ..
2021Hansa Biopharma AB to Initiate Phase 3 Study of Imlifidase to Treat Anti-Glomerular Bas..
2021Hansa Biopharma Nomination Committee formed
2021Hansa Biopharma Formed Nomination Committee
2021Hansa Biopharma Files for IPO on US Nasdaq
2021Hansa Biopharma announces it has confidentially submitted a draft registration statemen..
2021Transcript : Hansa Biopharma AB Presents at Gene Therapy Deep Dive, Nov-05-20..
2021Transcript : Hansa Biopharma AB - Special Call
2021Transcript : Hansa Biopharma AB, Nine Months 2021 Earnings Call, Oct 21, 2021
2021Hansa Biopharma: interim report Jan-Sept 2021
2021Hansa Biopharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended..
2021Hansa Biopharma: to host conference call to provide interim results for January-September..
2021Hansa Biopharma: presented new data on imlifidase at the European Society for Organ Trans..
2021Hansa Biopharma Presents New Data on Imlifidase At the European Society for Organ Trans..
Prossimo evento su HANSA BIOPHARMA AB (PUBL)